Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Katrak, J. Flood (2018)Latent Tuberculosis and Current Health Disparities in California: Making the Invisible Visible.
American journal of public health, 108 S4
R. Topić (2012)Latent tuberculosis infection
Heidi Fischer, L. Qian, J. Skarbinski, K. Bruxvoort, R. Wei, Kris Li, L. Amsden, Mariah Wood, A. Eaton, Brigitte Spence, Sally Shaw, S. Tartof (2022)Development and validation of a prediction algorithm to identify birth in countries with high tuberculosis incidence in two large California health systems
PLoS ONE, 17
M. Huaman, T. Sterling (2019)Treatment of Latent Tuberculosis Infection-An Update.
Clinics in chest medicine, 40 4
D. Menzies, M. Adjobimey, R. Ruslami, A. Trajman, O. Sow, H. Kim, J. Baah, G. Marks, R. Long, V. Hoeppner, K. Elwood, H. Al-Jahdali, M. Gninafon, L. Apriani, R. Koesoemadinata, A. Kritski, V. Rolla, B. Bah, A. Camara, I. Boakye, V. Cook, H. Goldberg, C. Valiquette, K. Hornby, M. Dion, P. Li, P. Hill, K. Schwartzman, A. Benedetti (2018)Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults
The New England Journal of Medicine, 379
(2015)Similarity of the adult Kaiser Permanente membership in Northern California to the insured and general population in Northern California: statistics from the 2011 California Health Interview Survey
T. Sterling, M. Villarino, A. Borisov, N. Shang, F. Gordin, E. Bliven-Sizemore, J. Hackman, C. Hamilton, D. Menzies, A. Kerrigan, S. Weis, M. Weiner, Diane Wing, M. Conde, L. Bozeman, C. Horsburgh, R. Chaisson (2011)Three months of rifapentine and isoniazid for latent tuberculosis infection.
The New England journal of medicine, 365 23
A. Borisov, S. Morris, Gibril Njie, C. Winston, D. Burton, S. Goldberg, R. Woodruff, Leeanna Allen, P. Lobue, A. Vernon (2018)Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection
Morbidity and Mortality Weekly Report, 67
Carol Mangione, Michael Barry, Wanda Nicholson, Michael Cabana, David Chelmow, Tumaini Coker, Esa Davis, Katrina Donahue, C. Jaén, Li Li, G. Ogedegbe, Goutham Rao, John Ruiz, James Stevermer, S. Underwood, John Wong (2023)Screening for Latent Tuberculosis Infection in Adults: US Preventive Services Task Force Recommendation Statement.
JAMA, 329 17
Samuel Holzman, A. Perry, P. Saleeb, Alexandra Pyan, C. Keh, K. Salcedo, M. Narita, Amina Ahmed, T. Miller, A. Pettit, R. Khurana, M. Whipple, D. Katz, A. Largen, Amy Krueger, M. Shah (2022)Evaluation of the latent tuberculosis care cascade among public health clinics in the United States.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
A. Sandgren, M. Noordegraaf-Schouten, F. Kessel, A. Stuurman, Anouk Oordt-Speets, M. Werf (2016)Initiation and completion rates for latent tuberculosis infection treatment: a systematic review
BMC Infectious Diseases, 16
(2021)Report on tuberculosis in California , 2019 . 2020 California tuberculosis elimination plan 2021 – 2025 : a five - year action plan
(2000)Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society
A. Mirzazadeh, J. Kahn, M. Haddad, A. Hill, S. Marks, A. Readhead, P. Barry, J. Flood, J. Mermin, P. Shete (2021)State-level prevalence estimates of latent tuberculosis infection in the United States by medical risk factors, demographic characteristics and nativity
PLoS ONE, 16
T. Sterling, Gibril Njie, D. Zenner, D. Cohn, R. Reves, Amina Ahmed, D. Menzies, C. Horsburgh, C. Crane, M. Burgos, P. Lobue, C. Winston, R. Belknap (2020)Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020
MMWR Recommendations and Reports, 69
D. Menzies, R. Long, A. Trajman, M. Dion, Jae Yang, H. Jahdali, Z. Memish, K. Khan, M. Gardam, V. Hoeppner, A. Benedetti, K. Schwartzman (2008)Adverse Events with 4 Months of Rifampin Therapy or 9 Months of Isoniazid Therapy for Latent Tuberculosis Infection
Annals of Internal Medicine, 149
Wansu Chen, L. Qian, Jiaxiao Shi, M. Franklin (2018)Comparing performance between log-binomial and robust Poisson regression models for estimating risk ratios under model misspecification
BMC Medical Research Methodology, 18
D. Cohn, R. O'brien, L. Geiter, F. Gordin, E. Hershfield (2014)Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection
Pediatric Clinical Practice Guidelines & Policies
A. McClintock, M. Eastment, C. McKinney, Caroline Pitney, M. Narita, David Park, S. Dhanireddy, A. Molnar (2017)Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine
BMC Infectious Diseases, 17
R. Miramontes, A. Hill, R. Woodruff, L. Lambert, T. Navin, K. Castro, P. Lobue (2015)Tuberculosis Infection in the United States: Prevalence Estimates from the National Health and Nutrition Examination Survey, 2011-2012
PLoS ONE, 10
D Menzies, R Long, A Trajman (2008)Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial
R. Belknap, D. Holland, Pei-Jean Feng, J. Millet, J. Caylà, N. Martinson, Alicia Wright, Michael Chen, R. Moro, Nigel Scott, Bert Arevalo, J. Miro, M. Villarino, M. Weiner, A. Borisov (2017)Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.
Annals of internal medicine, 167 10
H. Alsdurf, P. Hill, A. Matteelli, H. Getahun, D. Menzies (2016)The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis.
The Lancet. Infectious diseases, 16 11
C. Koebnick, A. Langer-Gould, M. Gould, C. Chao, Rajan Iyer, N. Smith, Wansu Chen, S. Jacobsen (2012)Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data.
The Permanente journal, 16 3
P. Lobue, J. Mermin (2017)Latent tuberculosis infection: the final frontier of tuberculosis elimination in the USA.
The Lancet. Infectious diseases, 17 10
BackgroundTreatment of latent tuberculosis infection (LTBI) is highly effective at preventing active tuberculosis (TB) disease. Understanding LTBI treatment practices in US health system settings is critical to identify opportunities to improve treatment prescription, initiation, and completion, and thus to prevent TB disease.MethodsWe assessed LTBI treatment practices among a cohort of adults after their first positive LTBI test (tuberculin skin test [TST] or interferon gamma release assay [IGRA]) between 2009 and 2018 at 2 large integrated health systems in California. We described the prescription, initiation, and completion of LTBI treatment (isoniazid [INH], rifampin, and rifamycin-INH short-course combinations) by demographic and clinical characteristics. We used multivariable robust Poisson regression to examine factors that were independently associated with treatment prescription and completion.ResultsAmong 79 302 individuals with a positive LTBI test, 33.0% were prescribed LTBI treatment, 28.3% initiated treatment, and 18.5% completed treatment. Most individuals were prescribed INH (82.0%), but treatment completion was higher among those prescribed rifamycin-INH short-course combinations (69.6% for INH + rifapentine and 70.3% for INH + rifampin) compared with those prescribed INH (56.3%) or rifampin (56.6%). In adjusted analyses, treatment prescription and completion were associated with older age, female sex, more comorbidities, immunosuppression, not being born in a high–TB incidence country, and testing positive with IGRA vs TST.ConclusionsLTBI treatment is underutilized, requiring tailored interventions to support treatment prescription and completion for patients with LTBI.
Open Forum Infectious Diseases – Oxford University Press
Published: Apr 21, 2023
Keywords: adherence; latent tuberculosis; treatment; tuberculosis
Access the full text.
Sign up today, get DeepDyve free for 14 days.